[Target molecules of molecular target therapy of cancer].
Department of Bioactive Molecules, National Institute of Infectious Diseases.
Yoshimasa
Y
Uehara
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D000077156:Gefitinib; D018832:Molecular Chaperones; D009369:Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018832:Molecular Chaperones; D011799:Quinazolines; D000069283:Rituximab; D000068878:Trastuzumab; D000077156:Gefitinib